Cárdenas Washington B, Loo Yueh-Ming, Gale Michael, Hartman Amy L, Kimberlin Christopher R, Martínez-Sobrido Luis, Saphire Erica Ollmann, Basler Christopher F
Department of Microbiology, Mount Sinai School of Medicine, 1 Gustave L. Levy Place, New York, NY 10029, USA.
J Virol. 2006 Jun;80(11):5168-78. doi: 10.1128/JVI.02199-05.
The Ebola virus (EBOV) VP35 protein blocks the virus-induced phosphorylation and activation of interferon regulatory factor 3 (IRF-3), a transcription factor critical for the induction of alpha/beta interferon (IFN-alpha/beta) expression. However, the mechanism(s) by which this blockage occurs remains incompletely defined. We now provide evidence that VP35 possesses double-stranded RNA (dsRNA)-binding activity. Specifically, VP35 bound to poly(rI) . poly(rC)-coated Sepharose beads but not control beads. In contrast, two VP35 point mutants, R312A and K309A, were found to be greatly impaired in their dsRNA-binding activity. Competition assays showed that VP35 interacted specifically with poly(rI) . poly(rC), poly(rA) . poly(rU), or in vitro-transcribed dsRNAs derived from EBOV sequences, and not with single-stranded RNAs (ssRNAs) or double-stranded DNA. We then screened wild-type and mutant VP35s for their ability to target different components of the signaling pathways that activate IRF-3. These experiments indicate that VP35 blocks activation of IRF-3 induced by overexpression of RIG-I, a cellular helicase recently implicated in the activation of IRF-3 by either virus or dsRNA. Interestingly, the VP35 mutants impaired for dsRNA binding have a decreased but measurable IFN antagonist activity in these assays. Additionally, wild-type and dsRNA-binding-mutant VP35s were found to have equivalent abilities to inhibit activation of the IFN-beta promoter induced by overexpression of IPS-1, a recently identified signaling molecule downstream of RIG-I, or by overexpression of the IRF-3 kinases IKKepsilon and TBK-1. These data support the hypothesis that dsRNA binding may contribute to VP35 IFN antagonist function. However, additional mechanisms of inhibition, at a point proximal to the IRF-3 kinases, most likely also exist.
埃博拉病毒(EBOV)的VP35蛋白可阻断病毒诱导的干扰素调节因子3(IRF-3)的磷酸化及激活,IRF-3是诱导α/β干扰素(IFN-α/β)表达的关键转录因子。然而,这种阻断发生的机制仍未完全明确。我们现在提供证据表明,VP35具有双链RNA(dsRNA)结合活性。具体而言,VP35可与聚(rI)·聚(rC)包被的琼脂糖珠结合,但不与对照珠结合。相比之下,发现两个VP35点突变体R312A和K309A的dsRNA结合活性严重受损。竞争试验表明,VP35与聚(rI)·聚(rC)、聚(rA)·聚(rU)或源自EBOV序列的体外转录dsRNA特异性相互作用,而不与单链RNA(ssRNA)或双链DNA相互作用。然后,我们筛选了野生型和突变型VP35靶向激活IRF-3的信号通路不同组分的能力。这些实验表明,VP35可阻断由RIG-I过表达诱导的IRF-3激活,RIG-I是一种细胞解旋酶,最近被认为可被病毒或dsRNA激活IRF-3。有趣的是,在这些试验中,dsRNA结合受损的VP35突变体具有降低但可测量的IFN拮抗剂活性。此外,发现野生型和dsRNA结合突变型VP35具有同等能力抑制由IPS-1过表达诱导的IFN-β启动子激活,IPS-1是最近在RIG-I下游鉴定出的信号分子,或抑制由IRF-3激酶IKKε和TBK-1过表达诱导的IFN-β启动子激活。这些数据支持dsRNA结合可能有助于VP35的IFN拮抗剂功能这一假说。然而,在接近IRF-3激酶的位点,很可能也存在其他抑制机制。